Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 5;10(5):e05808.
doi: 10.1002/ccr3.5808. eCollection 2022 May.

Atypical Parkinsonism: Methamphetamine may play a role

Mehri Salari  1 , Fatemeh Hojjati Pour  1 , Ronak Rashedi  1 , Masoud Etemadifar  2
Affiliations
Case Reports

Atypical Parkinsonism: Methamphetamine may play a role

Mehri Salari et al. Clin Case Rep. .

Abstract

Abusing methamphetamine can be considered as an agent that can cause or affect the course of atypical parkinsonian syndromes (APS), which may raise attention regarding preventing abusing these drugs.

Keywords: APS; Parkinsonism; atypical parkinsonism; methamphetamine.

PubMed Disclaimer

Conflict of interest statement

The authors do not have any conflict of interest.

Figures

FIGURE 1
FIGURE 1
Sagittal T2 and axial FLAIR and T2 MRI show generalized atrophy
FIGURE 2
FIGURE 2
Sagittal T2 and axial FLAIR MRI show generalized atrophy with prominent midbrain atrophy
See this image and copyright information in PMC

References

    1. Dickson DW. Parkinson’s disease and Parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2(8):a009258. - PMC - PubMed
    1. Levin J, Kurz A, Arzberger T, Giese A, Hoglinger GU. The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int. 2016;113(5):61‐69. - PMC - PubMed
    1. Deutschländer AB, Ross OA, Dickson DW, Wszolek ZK. Atypical Parkinsonian syndromes: a general neurologist’s perspective. Eur J Neurol. 2018;25(1):41‐58. - PMC - PubMed
    1. Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population‐based assessment. Drug Alcohol Depend. 2015;146:30‐38. - PMC - PubMed
    1. Kousik SM, Carvey PM, Napier TC. Methamphetamine self‐administration results in persistent dopaminergic pathology: implications for Parkinson’s disease risk and reward‐seeking. Eur J Neurosci. 2014;40(4):2707‐2714. - PubMed

Publication types

LinkOut - more resources